Stabilized liquid and lyophilized ADAMTS13 formulations
View Patent ↗The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
1. A stabilized aqueous formulation of ADAMTS13, comprising:
(a) 0.05 mg/ml to 10.0 mg/ml ADAMTS13;
(b) 0 mM to 100 mM of a pharmaceutically acceptable salt;
(c) 0.5 mM to 20 mM calcium;
(d) a sugar and/or sugar alcohol;
(e) a nonionic surfactant;
(f) a buffering agent; and
(g) a pH between 6.0 and 8.0.
2. The stabilized aqueous formulation of claim 1 , wherein the formulation comprises between about 50 units and about 1000 units of ADAMTS13 activity per ml.
3. The stabilized aqueous formulation of claim 1 , wherein the pharmaceutically acceptable salt is sodium chloride.
4. The stabilized aqueous formulation of claim 1 , comprising between 1.0 mM and 10.0 mM calcium.
5. The stabilized aqueous formulation of claim 1 , comprising between 2% and 6% sugar and/or sugar alcohol.
6. The stabilized aqueous formulation of claim 1 , wherein the sugar and/or sugar alcohol is selected from the group consisting of sucrose, trehalose, mannitol, and a combination thereof.
7. The stabilized aqueous formulation of claim 1 , wherein the sugar and/or sugar alcohol is a combination of sucrose and mannitol.
8. The stabilized aqueous formulation of claim 1 , comprising between 0.01% and 0.1% of a non-ionic surfactant.
9. The stabilized aqueous formulation of claim 1 , wherein the surfactant is selected from the group consisting of Polysorbate 20, Polysorbate 80, Pluronic F-68, and BRIJ 35.
10. The stabilized aqueous formulation of claim 1 , comprising between 5 mM and 100 mM of a buffering agent.
11. The stabilized aqueous formulation of claim 1 , comprising between 10 mM and 50 mM of a buffering agent.
12. The stabilized aqueous formulation of claim 1 , wherein the buffering agent is selected from the group consisting of histidine and HEPES.
13. The stabilized aqueous formulation of claim 1 , wherein the buffering agent comprises between 5 mM and 100 mM of a buffering agent selected from the group consisting of histidine and HEPES.
14. The stabilized aqueous formulation of claim 1 , wherein the formulation has a pH between 6.5 and 7.5.
15. The stabilized aqueous formulation of claim 1 , wherein the formulation has a pH of 7.0±0.2.
16. The stabilized aqueous formulation of claim 1 , comprising between 0.5 μM and 20 μM zinc.
17. The stabilized aqueous formulation of claim 1 , comprising between 0 mM and 90 mM of a pharmaceutically acceptable salt.
18. The stabilized aqueous formulation of claim 1 , comprising between 0 mM and 60 mM of a pharmaceutically acceptable salt.
19. The stabilized aqueous formulation of claim 1 , comprising between 0 mM and 30 mM of a pharmaceutically acceptable salt.
20. The stabilized aqueous formulation of claim 1 , comprising between 30 mM and 60 mM of a pharmaceutically acceptable salt.
21. The stabilized aqueous formulation of claim 1 , comprising between 30 mM and 90 mM of a pharmaceutically acceptable salt.
22. The stabilized aqueous formulation of claim 1 , comprising between 60 mM and 90 mM of a pharmaceutically acceptable salt.
23. The stabilized aqueous formulation of claim 1 , wherein the formulation comprises monomeric ADAMTS13 protein and a content of ADAMTS13 aggregates of less than 5% total protein.
24. The stabilized aqueous formulation of claim 1 , wherein the specific activity of the ADAMTS13 protein is at least about 600 U of FRETS-VWF73 activity per mg ADAMTS13 protein.
25. The stabilized aqueous formulation of claim 1 , wherein the formulation comprises:
(a) 0.05 mg/ml to 10.0 mg/ml ADAMTS13;
(b) 0 mM to 60 mM NaCl;
(c) 2 mM to 4 mM calcium;
(d) 2% to 4% mannitol;
(e) 0.5% to 2% sucrose;
(f) 0.025% to 0.1% Polysorbate 80;
(g) 10 mM to 50 mM histidine; and
(h) a pH of 7.0±0.2.
26. The stabilized aqueous formulation of claim 1 , wherein the formulation comprises:
(a) 0.05 mg/ml to 10.0 mg/ml ADAMTS13;
(b) 0 mM to 100 mM of a pharmaceutically acceptable salt;
(c) 0.5 mM to 20 mM calcium;
(d) a sugar and/or sugar alcohol;
(e) a nonionic surfactant;
(f) 5 mM to 100 mM of a buffering agent selected from the group consisting of histidine and HEPES; and
(g) a pH between 6.0 and 8.0.
27. The stabilized aqueous formulation of claim 1 , wherein the formulation comprises:
(a) 0.05 mg/ml to 10.0 mg/ml ADAMTS13;
(b) 0 mM to 100 mM of a pharmaceutically acceptable salt;
(c) 0.5 mM to 20 mM calcium;
(d) 2% to 6% of a sugar and/or sugar alcohol;
(e) a nonionic surfactant;
(f) 5 mM to 100 mM of a buffering agent selected from the group consisting of histidine and HEPES; and
(g) a pH between 6.0 and 8.0.
28. A kit comprising a stabilized aqueous ADAMTS13 formulation according to claim 1 .
29. A method for manufacturing a stabilized aqueous ADAMTS13 formulation, the method comprising the steps of:
(a) expressing an ADAMTS13 protein, or a biologically active derivative thereof, in a cell cultured in a medium comprising zinc at a concentration from about 2 μM to about 12 μM and calcium at a concentration from about 0.5 mM to about 1.5 mM;
(b) purifying the ADAMTS13 protein; and
(c) preparing a formulation according to claim 1 .